Drug Trial Radar · NCT02485899
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
Last checked: Nov 20, 2026Latest source record: Aug 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Feb 2015
Primary completion
Dec 10, 2020
Study completion Dec 10, 2020
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Jun 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase 1/2 study (190-201) evaluated the efficacy and safety of a 300 mg dose of BMN 190 administered every other week (qow) to patients with CLN2. The dose and regimen for this study (190-202) are based on the results of the 190-201 study. The rationale for this phase 2 extension study is to provide patients who complete the 190-201 study with the option to continue BMN 190 treatment. The 190-202 study is an open label extension protocol to assess long-term safety and efficacy.
Conditions
- Jansky-Bielschowsky Disease
- Batten Disease
- Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
- CLN2 Disease
- CLN2 Disorder
Interventions
BMN 190Biological
300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
Intracerebroventricular (ICV) access deviceDevice
Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Probability of Unreversed 2-point Decline in Motor-language (ML) Score or Score of 0Time frame: Up to Week 289
- Probability of Unreversed Motor-language (ML) Score of Zero.Time frame: Up to Week 289
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Nationwide Children's Hospital
Columbus, Ohio
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Children's Hospital Bambino Gesù,IRCCS
Rome, Piazza, Italy
Great Ormond Street Childrens Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.